An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Trial details
- Registry ID
- NCT06951217
- Drugs studied
- AP01
TrialRedline tracks 3 clinical trials sponsored by Avalyn Pharma Inc.: 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)NCT06951217 | AP01 | Recruiting | 2031-12-31Estimated |
| AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFNCT07194382 | AP02 | Recruiting | 2026-12Estimated |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401 | AP01 | Active not recruiting | 2027-06Estimated |
Names as written in the registry records.
NCT06329401 · Avalyn Pharma Inc.
Before: Estimated. After: Actual.
Before: 375 participants (planned). After: 398 participants (actual).
NCT06329401 · Avalyn Pharma Inc.
Before: Recruiting. After: Active not recruiting.
NCT07194382 · Avalyn Pharma Inc.
Before: Not yet recruiting. After: Recruiting.